The global new crown pneumonia epidemic continues, and how to find effective prevention methods is a top priority.
Kong Fanyi, a member of the Vaccine Advisory Committee and a clinical professor in the Department of Internal Medicine of the University of Hong Kong, said on a TV program today (21st) that the University of Hong Kong is conducting a "groove needle" study on the new crown vaccine. The third dose of booster, because Fubitai vaccine has higher protection against Delta variant virus than Kexing vaccine.
Kong also pointed out that it was observed that half of the study subjects had their antibody levels dropped to a low level half a year after receiving the second dose of vaccine. It is recommended that all those who have been vaccinated should be given a booster. "But Kexing is more urgent. Fubitai will be vaccinated first in the new year.” He also predicts that if the elderly vaccination rate increases, the government will formulate a third booster program for citizens to vaccinate in the short term.
Kong Fanyi pointed out that all those who participated in the study received full injection of Fubitai vaccine as the third booster.
(Profile picture / Photo by Luo Junhao)
Kong Fanyi pointed out that the University of Hong Kong is conducting a "groove needle" study on the new crown vaccine, emphasizing that it is safe and effective as a whole.
The research subjects are mainly people with compromised immune systems, including those who have undergone transplantation, received cancer chemotherapy, and who are taking biological agents or steroids.
He pointed out that all those who participated in the study were given full injection of Fubitai vaccine as the third booster, and half of them were injected intramuscularly and intracutaneously to see if there would be differences in antibody levels.
Kong also pointed out that because Fubitai vaccine produces antibodies against the Delta variant virus, which is stronger than Coxing vaccine, even if people with impaired immune systems are vaccinated, the overall neutralizing antibody performance is also good.
However, he also emphasized that "It does not mean Kexing does not have it." He said that Kexing vaccine is an inactivated vaccine and relies on antigens to produce protection.
However, the current antigen of Kexing vaccine is the "Wuhan First Generation". It is believed that if Kexing vaccine uses the most popular Delta variant virus as the antigen, it is believed that the effect will be more ideal.
▼On October 20th, members of the Legislative Council were vaccinated against influenza▼
+4
Kong Xu pointed out that it was observed that half of the study subjects had their antibody levels dropped to a low level or even close to negative half a year after receiving the second dose of vaccine. In particular, the decline of Kexing vaccine was faster than that of Fubitai vaccine.
He suggested that people who have been vaccinated with Kexing or Fubitai vaccine should be given a booster. "However, Kexing is more urgent, and Fubitai must be vaccinated in the next year."
Winter is approaching, which is conducive to the spread of the new crown virus.
Kong is concerned about the vaccinations of the elderly, saying that the immunization rate for elderly people over 70 is only about 30%, and he urges them to get vaccinated as soon as possible.
He predicts that if the elderly vaccination rate increases, the government will formulate a third booster program for citizens to vaccinate in the short term.
I asked a person who entered Israel from Europe and found the AY4.2 virus strain, the "Delta+" variant virus.
Kong Fanyi pointed out that there are two new mutations in the spike protein of Delta+. However, since people returning from overseas have not been infected with the virus strain, there is little knowledge about the virus strain in Hong Kong.
Researchers in the UK believe that Delta+ has a higher transmission power and is more likely to affect the protective effect of the vaccine, but there is no evidence to show that it is more destructive, and they believe that more influential data is needed to further understand.
New Crown Vaccine | 3,500 people received the first dose in a single day. One person had side effects after the injection in the hospital. New Crown Vaccine | 32 abnormal incidents after the injection were recorded in the past week and no potential deaths. New Crown Vaccine | New crown vaccine application | Public protection fund for paralyzed patients after acupuncture was rejected
01News
